Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.

MLA

Reissmann, T., et al. “Treatment of Experimental DMBA Induced Mammary Carcinoma with Cetrorelix (SB-75): A Potent Antagonist of Luteinizing Hormone-Releasing Hormone.” Journal of Cancer Research and Clinical Oncology, vol. 118, no. 1, 1992, pp. 44–49. EBSCOhost, https://doi.org/10.1007/BF01192310.

APA

Reissmann, T., Hilgard, P., Harleman, J. H., Engel, J., Comaru-Schally, A. M., & Schally, A. V. (1992). Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone. Journal of Cancer Research and Clinical Oncology, 118(1), 44–49. https://doi.org/10.1007/BF01192310

Chicago

Reissmann, T, P Hilgard, J H Harleman, J Engel, A M Comaru-Schally, and A V Schally. 1992. “Treatment of Experimental DMBA Induced Mammary Carcinoma with Cetrorelix (SB-75): A Potent Antagonist of Luteinizing Hormone-Releasing Hormone.” Journal of Cancer Research and Clinical Oncology 118 (1): 44–49. doi:10.1007/BF01192310.